LIGAND PHARMACEUTICALS (LGND)

US53220K5048 - Common Stock

73.1  +1.83 (+2.57%)

After market: 73.1 0 (0%)

Buy % Consensus

82

ChartMill assigns a Buy % Consensus number of 82% to LGND. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 119.14. This target is 62.98% above the current price.
LGND was analyzed by 11 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about LGND.
In the previous month the buy percentage consensus was at a similar level.
LGND was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target & Forecast

Price Low Median Mean High 73.1095.95112.20119.14151.20 - 31.26% 53.49% 62.98% 106.84%
Up and Down Grades
Date Firm Action Rating
2024-02-29 HC Wainwright & Co. Reiterate Buy -> Buy
2023-12-13 Benchmark Reiterate Buy -> Buy
2023-09-19 HC Wainwright & Co. Reiterate Buy -> Buy
2023-08-23 Benchmark Reiterate Buy -> Buy
2023-08-09 HC Wainwright & Co. Reiterate Buy -> Buy
2023-07-25 Barclays Maintains Overweight -> Overweight
2023-06-02 HC Wainwright & Co. Reiterate Buy -> Buy
2023-02-21 Benchmark Reiterate Buy
2022-12-23 Roth Capital Maintains Buy
2022-11-21 Barclays Maintains Overweight
2022-10-25 Barclays Maintains Overweight
2022-09-02 Roth Capital Maintains Buy
2022-07-05 Barclays Maintains Overweight
2022-05-16 Stephens & Co. Maintains Overweight
2022-02-22 Benchmark Maintains Buy
2022-02-18 Barclays Maintains Overweight
2021-09-22 Barclays Maintains Overweight
2021-07-30 Roth Capital Maintains Buy
2021-05-04 Barclays Maintains Overweight